Clinical Practice Diabetes Education Clinical Research Physician Profiles What's New? F-A-Q's Map to DGD |
Physician Profiles
Mark S. Kipnes, M.D. |
Fellowship, Endocrinology, George Washington University Medical Center, Washington, DC, Kenneth L. Becker, MD, PhD, Chief, Endocrinology and Metabolism, Postgraduate, July 1982 to June 1984.
Residency, Internal Medicine, Mercy Hospital, Pittsburgh, PA, Frank J. Luparello, MD, Chairman, Department of Medicine, Postgraduate, June 1980 to June 1982.
Internship, Medicine, Mercy Hospital, Pittsburgh, PA, Frank J. Luparello, MD, Chairman, Department of Medicine, Postgraduate, July 1979 to June 1980.
MD, Hahnemann Medical College, Philadelphia, PA, Graduate, June 1979
Bachelor of Science in Life Science, Philadelphia College of Textiles and Sciences, Philadelphia, PA, Undergraduate, May 1975
American Board of Endocrinology and Metabolism
American Board of Internal Medicine
Clinical Professor in Medicine/General Medicine, The University of Texas Health Science Center at San Antonio, September 1, 2001 through present
Clinical Instructor, University of Texas Health Science Center at San Antonio, 1986 to 2001
Professional Membership
Member of the Development Committee, The Endocrine Society, 2002 – 2005
Member of the Diabetes Expert Panel for Human Genome Sciences, 2002 - present
National Glucophage Speakers’ Bureau, 1996
American Association of Clinical Endocrinologists, 1992 - present
The Endocrine Society, 1992 - present
Bexar County Medical Society, 1985 - present
American Diabetes Association, 1983 - present
American College of Physicians, 1982 - present
National Board of Medical Examiners, 1980 – present
Pharmaceutical Advisory Board Appointments
Genaera Advisory Board, current
Lilly ICOS U.S. Cialis Cardiology/Endocrinology Advisory Board, current
Jansen Advisory Board, current
Nobex Advisory Board, current
Insmed Clinical Advisory Board, current
CHRISTUS Santa Rosa Medical Center
2827 Babcock Road
San Antonio, Texas 78229
Methodist Specialty & Transplant Hospital
(Formerly San Antonio Community Hospital)
8026 Floyd Curl Drive
San Antonio, Texas 78229
Southwest Texas Methodist Hospital
7700 Floyd Curl Drive
San Antonio, Texas 78229
St. Luke’s Baptist Hospital
7930 Floyd Curl Drive
San Antonio, Texas 78229
Methodist Children’s Hospital
(Formerly Methodist Women’s & Children’s Hospital)
7700 Floyd Curl Drive
San Antonio, Texas 78229
Professional Activities
Chief of Staff, Methodist Specialty & Transplant Hospital (formerly San Antonio Community Hospital), 1997
Vice Chief of Staff, Methodist Specialty & Transplant Hospital (formerly San Antonio Community Hospital), 1996.
Chief of Staff Alternate, Methodist Specialty & Transplant Hospital (formerly San Antonio Community Hospital), 1995
Secretary, Medical Staff Executive Committee, Methodist Specialty & Transplant Hospital (formerly San Antonio Community Hospital), 1994
Chairman, Department of Medicine, Methodist Specialty & Transplant Hospital (formerly San Antonio Community Hospital), 1993 - 1994
Co-Director, 10th South Texas Clinical Diabetes Symposium (Seventh Annual), San Antonio, Texas, 1992
Co-Director, 9th South Texas Clinical Diabetes Symposium (Sixth Annual), San Antonio, Texas, 1991
Co-Director, 8th South Texas Clinical Diabetes Symposium (Fifth Annual), San Antonio, Texas, 1990
American Diabetes Association Texas Affiliate, Board of Directors, 1988 - 1990
Co-Director, 7th South Texas Clinical Diabetes Symposium (Fourth Annual), San Antonio, Texas, 1989
Co-Director, 6th South Texas Clinical Diabetes Symposium (Third Annual), San Antonio, Texas, 1988
Co-Director, 5th South Texas Clinical Diabetes Symposium (Second Annual), San Antonio, Texas, 1987
Co-Director, 4th South Texas Clinical Diabetes Symposium (First Annual), San Antonio, Texas, 1986
Co-Director, 3rd Bi-Annual South Texas Clinical Diabetes Symposium, San Antonio, Texas, 1985
Co-Director, 5K Diabetes Run, Humanathon, 1984 - 1987
Associate Director, Diabetes & Glandular Disease Clinic, San Antonio, Texas, July 1984 - present
Associate Director, Diabetes & Glandular Disease Research Associates, P.A., San Antonio, Texas, July 1984 – present.
Update on Diabetes, PM&R Quarterly Conference, RIOSA, 1994
Town Hall Meetings (Diabetes Mellitus Updates), 1984 - 1994
Update on Diabetes, PM&R Noon Conference, St. Rose Hospital, San Antonio, Texas, September 1992
Islet Cell Antibodies, American Diabetes Association, Waco, Texas, 1988
Gestational Diabetes, Nursing Unit, Methodist Children’s Hospital (formerly Methodist Women’s & Children’s Hospital), San Antonio, Texas, 1986
Newer Aspects of Insulin Management, San Antonio Pharmacists, San Antonio, Texas, 1986
Osteoporosis, Uvalde Hospital, Uvalde, Texas, 1986
Oral Agent Therapy of Diabetes, Kerrville, Texas, 1985
Osteoporosis, Department of Family Practice, University of Texas Health Science Center at San Antonio, Texas, 1985
Publications
Placebo-Controlled Trial." Andrew J. Lewin, MD¹, Mark S. Kipnes, MD², Luigi F. Meneghini, MD³, Diane J. Plotkin,
PhD, Inna T. Perevozskaya, PhD, Sukrut Shah, PhD, Darbie L. Maccubbin, PhD, Yale B. Mitchel, MD and Jonathan
A. Tolbert, MD for the Simvastatin/Thiazolidinedione Study Group*. Clinical Therapeutics / Vol. 26, No. 3, 2004.
“Control of Postprandial Plasma Glucose by an Oral Insulin Product (HIM2) in Patients With Type 2 Diabetes”. Mark S. Kipnes, MD1; Paresh Dandona, MD2; Devjit Tripathy; MD2; J. Gordon Still, PhD3.; Gordana Kosutic, MD3 Diabetes Care Volume 26, Number 2, February 2003, pp:421-426, 2003.
“Glycemic and Insulinemic Responses of Nondiabetic Healthy Adult Subjects to an Experimental Acid-Induced Viscosity Complex Incorporated Into a Glucose Beverage. Bryan W. Wolf, Ph.D., Chron-Si Lai, Ph.D., Mark S. Kipnes, M.D., Deborah G. Ataya, Ph.D., Keith B. Wheeler, Ph.D., Bradley A. Zinker, Ph.D., Keith A. Garleb, Ph.D., and Jeffrey L. Firkins, Ph.D. Nutrition Volume 18, Numbers 7/8, ,2002 pp:621-626. ©Elsevier Science Inc., 2002.
“Use of Three Clinical Performance Guidelines to Evaluate Modified Glucose Strips.” Mark S. Kipnes, M.D., Sawn M. Bina, M.D. Judy O Joynes, M.D., Ann Tideman, M.D. San Antonio, Texas. Diabetes, A Journal of the American Diabetes Association, June 14-18, 2002, Volume 51, Supplement 2.
“Long Term Effect of Glitazones in Clinical Practice.” William F. Trigoso, M.D., Jacob Vadakekalam, M.D., Sherwyn L. Schwartz, M.D. Jerome S. Fischer, M.D., Mark S. Kipnes, M.D., Amna A. Salhin, M.D., Daina Dreimane, M.D. Litza Loza. San Antonio, Texas. Diabetes, A Journal of the American Diabetes Association, June 14-18, 2002, Volume 51, Supplement 2.
“Continuous Subcutaneous Infusion of Recombinant GLP-1 for 7 Days Dose Dependently Improved Glycemic Control in Type 2 Diabetes.” Mario R. W. Ehlers, M.D., Roderick E. Harley, M.D., Roberta L. Schneider, M.D., Mark S. Kipnes, M.D.. Lincoln Nebraska; San Antonio, Texas. Diabetes, A Journal of the American Diabetes Association, June 14-18, 2002, Volume 51, Supplement 2.
“Which Patients Do Not Require a GH Stimulation Test for the Diagnosis of Adult GHH Deficiency?" Mark L. Hartman; Brenda J. Crowe; Beverly M. K. Biller; Ken K. Y. History of; David R. Clemmons and John J. Chipman, ON BEHALF OF THE HYPOCCS ADVISORY BOARD AND THE U.S. HYPOCCS STUDY GROUP*. Published in The Journal of Clinical Endocrinology & Metabolism. February 2002, Volume 87. No. 2. pp. 477-485.
“Effects of Losartan on Renal and Cardiovascular Outcomes In Patients With Type 2 Diabetes and Nephropathy”. Barry M. Brenner, M.D.; Mark E. Cooper E. Cooper, M.D.; Dick De Zeeuw, M.D.; William F. Keane, M.D.; William E. Mitch, M.D.; Hans-Henrik Parving, M.D.; Guiseppe Remuzzi, M.D.; Steven M. Snapinn, Ph.D.; Zhonxin Zhang, Ph.D., and Shahnaz Shahinfar, M.D.; for the RENAAL Study Investigators*. Published in The New England Journal of Medicine, September 20, 2001, Volume 345, Number 12; pp. 861-868.
“Pioglitazone Hydrochloride in Combination with Sulfonylurea Therapy Improves Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled Study.” Mark S. Kipnes, et al., published in The American Journal of Medicine, July 2001, Volume 111, Number 1, published by Elsevier Science.
“Sugar-Free Zinc Gluconate Glycine Lozenges (Cold Eeze®) Do Not Adversely Affect Glucose Control in Patients with Type 1 or Type 2 Diabetes Mellitus”. Sherwyn L. Schwartz, M.D.; Jerome S. Fischer, M.D.; Mark S. Kipnes, M.D. American Journal Of Therapeutics, 1075-2765 © 2001 Lippincott Willisms & Wilkins pp. 006-0611
“Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis, A Randomized Controlled Trial”. Steven T. Harris, M.D.; Nelson B. Watts, M.D.; Harry K. Genant, M.D.; Clark D. McKeever, M.D.; Thomas Hangartner, Ph.D.; Michael Keller, M.D.; Charles H. Chesnut III, M.D.; Jaques Brown, M.D.; Erik F. Eriksen, M.D.; Mohammed S. Hoseyni, Ph.D.; Douglas W. Axelrod, M.D., Ph.D. and Paul D. Miller, M.D. for the Vertebral Efficacy With Risedronate Therapy (VERT) Study Group*. The Journal of the American Medical Association, October 13, 1999, Volume 282, number 14, pp. 1344 – 1352
“Glycemic Response To An Induced -Viscosity Complex Incorporated Into A Glucose Beverage In Healthy Adult Subjects”. B.W. Wolf, C.-S. Lai, M. S. Kipnes, K. B. Wheeler and K. A. Garleb, MDs. The FASEB Journal, March 1998, Abstracts Part I, Volume 12, Number 4
“Testosterone Pharmacokinetics after Application of an Investigational Transdermal System in Hypogonadal Men” …Zhiling Yu, PhD, Suneel K. Gupta, PhD, Stephen s. Hwang, PhD, Mark S. Kipnes, MD, Arshag D. Mooradian, MD, Peter J. Snyder, MD. Journal Clinical Pharmacology December 1997 Issue, http://www.accp1.org - 11k - Cached - Similar pages
“Management of Gestational Diabetes in the Obese Patient”. Terri Ryan, RN, CDE; Jasso-Glavy, Carla, MS, RD, CDE; Kipnes, Mark S., M.D. and their health care team. Diabetes Spectrum, July/August 1995, Volume 8, Number 4, pp. 190 -191
“Adverse Effects of Recombinant Human Insulin-Like Growth Factor I in Obese Insulin-Resistant Type II Diabetic Patients”. Jabri, Nabeel, MD. ; Schalch, Don S., MD; Schwartz, Sherwyn L. , MD; Fischer, Jerome S., MD; Kipnes, Mark S., MD; Radnik, Barbara J., RN; Turman, Nancy J., MD; Marcisin , Victoria S., MD and Guler, Hans-Peter, MD. Diabetes, A Journal of the American Diabetes Association, March 1994, Volume 43
“Effects of Short -Term Insulin Therapy upon Therapeutic Response to Glipizide”. Schwartz, Sherwyn, MD; Fischer, Jerome S., MD; Kipnes, Mark S., MD and Boyle, Mary, RN., The American Journal of Medicine, September 18, 1987, Volume 83, Supplement 3A, pp. 22 – 30
“Guidelines to Diabetes Management for the Primary Care Physician”, Editorial Board, Professional Education Committee, American Diabetes Association Texas Affiliate, 1985
"Effect of Mitemcinal Fumarate (GM-611) on Gastric Emptying, Safety and Tolerability With Diabetic or Idiopathic Gastroparesis". Endo 2004 Meeting for poster presentation. Friday, June 18, 2004, 11:00 to 12:00 & 2:30 p.m. to 3:30 p.m., Exhibit Hall, poster Board #P3-577. Chugai Pharma.
"Safety of Mitemcinal Fumarate (GM-611) in Patients With Symptomatic Gastroparesis". A.D.A. 2004 as a poster presentation. Saturday, June 5, 2004, 12:15 p.m. to 2:15 p.m. & 5:00 p.m. to 6:00 p.m. Chugai Pharma.
"Effect of Mitemcinal Fumarate (GM-611) on Gastric Emptying in Patients With Idiopathic Or Diabetic Gastroparesis". Digestive Disease Week (DDW) 2004 meeting for a AGA Poster Session in May. Tuesday, May 18, 2004, Abstract ID#: 103158, Poster Session ID#: 1817, Session Type: Gastric Motility and Sensation. 12:00 to 2:00 p.m.
"Comparing The Efficacy And Tolerability of Metformin XT QD to Immediate-Release Metformin BIDD in Patients With Type 2 Diabetes". AACE 2004 as a poster presentation. Mark S. Kipnes, MD¹, Prachi K. Drandekar, Pharm.D.². Friday, April 30, 2004 from 9:45 to 10:30 a.m. Andrx Labs, Inc., 411 Hackensack Ave., Hackensack, New Jersey 07601, U.S.A.
"Comparison of Extended-Release Metformin with the Evening Meal to Immediate-Release Metformin bid in Type 2 Diabetes". Mark S, Kipnes, MD¹, Prachi K. Drandekar, Pharm.D.². Friday, April 30, 2004 from 9:45 to 10:30 a.m. Andrx Labs., Inc., 411 Hackensack Ave., Hackensack, New Jersey 07601, U.S.A.
Plasma Glucose and Insulin Response to Isocaloric Amounts of Enteral Formulas in Persons with Type 2 Diabetes Mellitus. S.L. Schwartz, M.D.; J. Fischer, M.D.; M. Kipnes, M.D. and L. Kelly, R.N. Diabetes and Glandular Disease Research Center, San Antonio, TX. Currently used by Norvartis Nutritional, in their brochures and on their Website. January, 2003.
“Efficacy and Safety of Treatment With Simvastatin in Thiazolidinedione-Treated Type 2 Diabetic Patients.” M. S. Kipnes1, A. J. Lewin2, L. F. Meneghini3, I. Perevozskaya4, S. Shah4, D. Plotkin, J. Tobert4; 1Diabetes & Glandular Disease Research Associates, P.A., San Antonio, TX, 2National Research Institute, Los Angeles, CA, 3University of Miami School of Medicine Diabetes Research Institute, Miami, FL, 4Merck Research Laboratories, Rahway, NJ. European Association for the Study of Diabetes (EASD2002). March 29, 2002.
“Durability of Glycemic Control with Pioglitazone in Long-Term Combination and Monotherapy”. DANIEL EINHORN, MARK KIPNES, N. BRADLEY GLAZER, WILLIAM WISHNER, PIOGLITAZONE STUDY GROUP. San Diego CA; San Antonio, TX; Lincolnshire, IL. Diabetes, A Journal of The American Diabetes Association, Abstract Book, 61st Scientific Sessions, Monday, June 25, 2001. Volume 50, Supplement 2.
“COMMUNITY SCREENING FOR DIABETES: SHOULD DEMOGRAPHICS BE A FACTOR”? Mark S. Kipnes, Sherwyn L. Schwartz, Jerome S. Fischer, William F. Trigoso, Amna A. Salhin, Jacob Vadakekalam, Daina Dreimane, William D. Linn. American Association of Clinical Endocrinologists 10th Annual Meeting & Clinical Congress. May 2-6, 2001. San Antonio, Texas.
“Pioglitazone Hydrochloride in Combination with Metformin in the Treatment of Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled Study. Daniel Einhorn MD1, Marc Rendell, MD2, James Rosenzweig, MD3, John W. Egan,4 Annette L. Mathisen, PhD4 and Roberta L. Schneider, MD4, for the Pioglitazone 027 Study Group* 1Diabetes and Endocrine Associates and Sharp HealthCare, San Diego, California, 2Creighton Diabetes Center, Omaha, Nebraska, and the Rose Salter Medical Research Foundation, Baltimore, Maryland, 3Joslin Diabetes Center, Boston, Massachusetts, and 4Takeda America Research and Development Center, Inc, Princeton, New Jersey. Clinical Therapeutics.2000;22:1395-1409. Parts of this work were presented at the 59th Annual Meeting and Scientific Sessions of the American Diabetes Association, June 19-20, 1999, San Diego, California, and published as an abstract in Diabetes, Supplement 1, May 1999. *Members of the Pioglitazone 027 Study Group are listed in the Acknowledgements. *Mark S. Kipnes: Part of 027 the Study Group.
“A Comparison of the Pharmacodynamic Effects of Inhaled Insulin versus Subcutaneous Insulin in Type 1 Diabetic Patients”. MARK KIPNES, BABATUNDE OTULANA, PER CLAUSON, JEROME FISCHER, STEPHEN J. FARR, VIBEKE HATORP, SHERWYN SCHWARTZ, HAYWARD, CA. Diabetes, A Journal of the American Diabetes Association, Abstract Book, 59th Scientific Sessions, May 1999, Volume 48, Supplement I, pp. A95.
*M.S. Kipnes – member of study group
Poster Presentations
"Effect of Mitemcinal Fumarate (GM-611) on Gastric Emptying, Safety and Tolerability With Diabetic or Idiopathic Gastroparesis". Endo 2004 Meeting for poster presentation. Friday, June 18, 2004, 11:00 to 12:00 & 2:30 p.m. to 3:30 p.m., Exhibit Hall, Poster Board #P3-577. Chugai Pharma.
"Safety of Mitemcinal Fumarate (GM-611) in Patients With Symptomatic Gastroparesis". A.D.A. 2004 as a poster presentation. Saturday, June 5, 2004, 12:15 to 2:15 p.m. & 5:00 p.m. to 6:00 p.m. Chugai Pharma.
"Effect of Mitemcinal Fumarate (GM-611) on Gastric Emptying in Patients With Idiopathic or Diabetic Gastroparesis". Digestive Disease Week (DDW) 2004 meeting for a AGA Poster Session in May. Tuesday, May 18, 2004, Abstract ID#: 103158, Poster Session ID#: 1817, Session Type: Gastric Motility and Sensation. 12:00 to 2:00 p.m.
"Comparing The Efficacy And Tolerability of Metformin XT QD to Immediate-Release Metformin BIDD In Patients With Type 2 Diabetes". AACE 2004 as a poster presentation. Friday, April 30, 2004 from 9:45 to 10:30 a.m. Andrx Labs.
Impact of Achieved Systolic Blood Pressure On Renal Function In Type 2 Diabetic Nephropathy. Marc A. Pohl, MD1; Samuel Blumenthal, MD2; Lawrence G. Hunsicker, MD3 and The Collaborative Study Group4. 1Cleveland Clinic Fdn., Cleveland Ohio; 2Veterans Administration, Milwaukee, Wisconsin; 3University of Iowa Hospitals and Clinics, Iowa City, Iowa and 4Rush Medical College, Chicago, Illinois. Presented at the ASN Meeting, November 2002.
Impact Of Angiotensin Receptor Blockade With Irbesartan On Renal Function At Different Systolic Blood Pressure (SBP) Levels In Type 2 Diabetic Nephropathy. Marc A. Pohl, MD1; Daniel J. Cordonnier, MD2; Samuel Spitalewitz, MD3 and The Collaborative Study Group4. 1Cleveland Clinic Foundation, Cleveland Ohio; 2University of Grenoble, Grenoble, France; 3Brooklyn Hospital Medical Center, Brooklyn, NY and 4Rush Medical College, Chicago, Illinois. Presented at the ASN Meeting, November 2002.
The Severity Of Orthostatic Hypotension Is A Risk Factor In The Progression Of Type 2 Diabetic Nephropathy. Matthew R. Weir, MD and Lawrence G. Hunsicker, MD, for The Collaborative Study Group, Chicago Illinois. Presented at the ASN Meeting, November 2002.
The Presence Of Retinopathy Is Associated With Poor Renal And Cardiovascular Outcomes In Type 2 Diabetic Nephropathy. Roger Rodby, MD1; Richard Gilbert, MD2, for The Collaborative Study Group, 1Chicago, Illinois USA. 2Victoria, Australia. Presented at the ASN Meeting, November 2002.
Predictors Of The Progression Of Renal Insufficiency In Patients With Type 2 Diabetes And Overt Diabetic Nephropathy. John P. Middleton, Julia Lewis, for The Collaborative Study Group University of Texas Southwestern, Dallas, Texas; Vanderbilt University, Nashville, Tennessee. Presented at the ASN Meeting, November 2002.
Cardiovascular Outcomes In The Irbesartan Diabetic Nephropathy Trial (IDNT) Of Patients With Type 2 Diabetes And Overt Nephropathy. Tomas Berl, MD1 for The Collaborative Study Group2. 1Division of Renal Diseases and Hypertension, University of Colorado2, Denver, Colorado Department of Medicine, Rush Medical Center, Chicago, Illinois. Presented at the ASN Meeting, November 2002.
“Albutropinä In Subjects With Adult Growth Hormone Deficiency.” Anne Klibanski, M.D.1, Mark Kipnes, M.D.2, David Kleinberg, M.D. 3, David Cook, M.D.4, Peter Snyder, M.D.5, Maria Walker6 and Daniel Odenheimer, PhD7.
1Massachusetts Genefal Hospital, Boston, MA, 02114; 2Diabetes and Glandular Disease Clinic, San Antonio, TX, 78229; 3New York University School of Medicine, New York, NY, 11016; 4Oregon Health Sciences University, Portland, OR, 97201; 5University of Pennsylvania, Philadelphia PA, 19104; 6Human Genome Sciences, Rockville, MD, 20850; 7Human Genome Sciences, Rockville, MD, 20850. Presented at the First Joint Symposium GH-IGF-2002. October 8, 2002.
“Efficacy and Safety of Treatment With Simvastatin in Thiazolidinedione-Treated Type 2 Diabetic Patients.”
M. S. Kipnes1, A. J. Lewin2, L. F. Meneghini3, I. Perevozskaya4, S. Shah4, D. Plotkin, J. Tobert4; 1Diabetes & Glandular Disease Research Associates, P.A., San Antonio, TX, 2National Research Institute, Los Angeles, CA, 3University of Miami School of Medicine Diabetes Research Institute, Miami, FL, 4Merck Research Laboratories, Rahway, NJ.
Poster Number 1205. Presented at the 38th EASD Annual Meeting, Budapest, Hungary, September 1-5, 2002.
“Impact of Use of Insulin, Glargine, on Hbg A1c and BMI in a Specialty (Endocrine) Practice Population.” Jerome S. Fischer, M.D. Riad G. Dirani, M.D., Sherwyn L. Schwartz, M.D., Mark S. Kipnes, M.D., Fernando W. Trigoso, M.D., Amna A. Salhin, M.D., Jacob Vadakekalam, M.D., Daina Dreimane, M.D., Litza Loza, San Antonio, Texas. For presentation at the American Diabetes Association 62nd Scientific Sessions, June 14-18, 2002, San Francisco, California.
“Effects of Multiple Doses of Orally Administered Hexyl Insulin M2 (HIM2) on Postprandial Blood Glucose (PPG) Concentrations in Type 1 Diabetic (T1) Patients.” Stephen Clement, M.D., Mark S. Kipnes, M.D., Helmut Steinberg, M.D., S. Edwin Fineberg, M.D., Louis Jovanovic, M.D., Nancy Rikalo, M.D., Jennifer Marks, M.D., Diana Gibson, M.D., J. Gordon Still, M.D., Gordana Kosutic, M.D. For presentation at the American Diabetes Association 62nd Scientific Sessions, June 14-18, 2002, San Francisco, California.
“Glycemia control and Lipid Profile in Type 2 Diabetes are Improved by Long-Term Pioglitazone/Sulfonylurea Combination Therapy.” M. Menon-Raju, M. Kipnes, and NB Glazer. Takeda Pharmaceuticals North American, Inc., Lincolnshire, IL, USA; Diabetes & Glandular Disease Clinic, San Antonio, TX, USA. Presented at The Diabetes UK Annual Conference, March 13-15, 2002. Birmingham, UK.
“Glycemic Control in Type 2 Diabetes is Improved by Long-Term Pioglitazone/Sulfonylurea Combination Therapy.” M. Kipnes1 and A. Boss.2 For presentation at the 37th Annual Meeting of the European Association for the Study of Diabetes. September 9 – 13, 2001. Glasgow, Scotland. Hosted by Diabetes UK. Dr. Michael Hall Chairman.
“The Effects of an Oral Modified Insulin on Postprandial Blood Glucose Levels in Patients with Type 2 Diabetes Mellitus”. Mark S. Kipnes, Paresh Dandona, J. Gordon Still, Gordana Kosutic. Diabetes and Glandular Disease Clinic, San Antonio, TX; Diabetes-Endocrinology Center of Western, Buffalo, NY; Nobex Corporation, Research Triangle, NC. For presentation at the President’s Poster Session and Reception, American Diabetes Association 61st Scientific Sessions, Sunday, June 24, 2001, Philadelphia Pennsylvania.
“Clinical Utility of rhTSH-stimulated Thyroglobulin Testing Without Scan in Management of Differentiated Thyroid Cancer”. Leonard Wartofsky, M.D.; Washington Hospital Center Washington, D.C. For the rhTSH-Stimulated Thyroglobulin Investigators Group*, supported by a Research Grant from Genzyme Corp., Boston, Mass. Poster For presentation at the Endocrine Society Annual Meeting in Denver Thursday, June 21, 2001.
“THE AVANDIA WORLDWIDE AWARENESS REGISTRY (AWAReÒ): AN INTERNET-BASED PROGRAM FOR EVALUATION OF CLINICAL, HUMANISTIC AND ECONOMIC OUTCOMES OF PATIENTS WITH TYPE 2 DIABETES.” Bakst A.W., Meletiche D.M., Arnold R., Pettit K., Harjono H., Najib M., Cobitz A., Schwartz S., Kipnes M., Fischer J., GlaxoSmithKline, Collegeville PA, Pharmacon International, New York, N.Y. Poster presented at ISPOR meeting May, 2001.
A Clinical Trial In Patients With Overt Type 2 Diabetic Nephropathy. EJ Lewis; LG Hunsicker; WC Clarke for The Collaborative Study Group, Chicago IL and Iowa City, Iowa. Presented at the ASN meeting November 2001.
“Pharmacokinetics and Pharmacodynamics of Pulmonary Insulin Delivered via the AERxÒ Insulin Diabetes Management System in Type 1 Diabetics”. M. Kipnes, B. Otulana, S. Farr, J. Jendle, J. Thipphawong and S. Schwartz. For presentation at the 36th Annual Meeting of The European Association for the Study of Diabetes, held at the Jerusalem ICC - International Convention Center and the adjacent Crowne Plaza Hotel, September 18, 2000, Jerusalem, Israel.
“Effects of Troglitazone on HbA1c and ALT Levels in Clinical Practice”. Sherwyn L. Schwartz, M.D., Jerome S. Fischer, M.D., Mark S. Kipnes, M.D., San Antonio, TX. For presentation at the President’s Poster Session and Reception, American Diabetes Association 59th Scientific Sessions, June 20, 1999, San Diego, CA.
Clinical Trials Listing available upon request.
E-mail / Web Page Address
E-mail: webmaster@dgdclinic.com
Web Page: www.dgdclinic.com
Home Clinical Practice Diabetes Education Clinical Research Physician Profiles What's New? F-A-Q's Map to DGD |
© 1979- 2007 DGD